VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | Improved survival of myelofibrosis patients receiving ruxolitinib post allo-HSCT

Eleni Gavriilaki, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discussess the long-term safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients with myelofibrosis. Data from 12 patients was analyzed in a retrospective study, which reported that patients who received ruxolitinib following alloHCT did not suffer from treatment-related mortality, and that the two-year disease-free survival for patients who received ruxolitinib following alloHCT was 75%, compared to 14.3% for patients who did not receive ruxolitinib. Two-year overall survival was significantly improved in patients who received ruxolitinib following alloHCT. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

Eleni Gavriilaki, MD, PhD, has participated in consultancy work with Alexion and Omeros Corporation.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter